HomeAI · summaries
Storia in 20 fonti
‘Landmark’: New mRNA vaccine could prevent skin cancer from returning, companies say
Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna…
- ·
en.mercopress.com
A personalized mRNA therapy passes a phase 3 melanoma trial for the first time
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran…
